[{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Ridgeback Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Drug Innovation Ventures at Emory \/ Ridgeback Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Drug Innovation Ventures at Emory \/ Ridgeback Biotherapeutics"},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Innovation Ventures at Emory \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Drug Innovation Ventures at Emory \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Drug Innovation Ventures at Emory

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          China Battery Fair
                          Not Confirmed
                          China Battery Fair
                          Not Confirmed

                          Details : Ridgeback has exclusively licensed DRIVE's EIDD-2801 and will be responsible for advancing it through clinical development and ensuring that EIDD-2801 is available during current pandemic.

                          Product Name : EIDD-2801

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 23, 2020

                          Lead Product(s) : Molnupiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Ridgeback Biotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          China Battery Fair
                          Not Confirmed
                          China Battery Fair
                          Not Confirmed

                          Details : DRIVE is developing the compound, designated EIDD-2801, which has shown efficacy against other coronaviruses such as SARS-CoV and MERS-CoV.

                          Product Name : EIDD-2801

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 27, 2020

                          Lead Product(s) : Molnupiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank